Takeda Pharmaceuticals U.S.A., Inc.
🇺🇸United States
Clinical Trials
0
Active:0
Completed:0
Trial Phases
0 Phases
Drug Approvals
12
NMPA:8
CANADA:2
Drug Approvals
Susoctocog Alfa for Injection
- Product Name
- 助因止
- Approval Number
- 国药准字SJ20240009
- Approval Date
- Feb 20, 2024
NMPA
Mobocertinib Succinate Capsules
- Product Name
- 安卫力
- Approval Number
- 国药准字HJ20230001
- Approval Date
- Jan 10, 2023
NMPA
Clinical Trials
No trials found
News
Lupin Gains FDA Approval for Generic Adderall XR for ADHD Treatment
• Lupin has received FDA approval for its generic version of Adderall XR, an extended-release capsule used to treat ADHD in adults and children. • The approved Abbreviated New Drug Application (ANDA) includes multiple dosage strengths, ranging from 5 mg to 30 mg. • Lupin's generic equivalent of Adderall XR is poised to enter a market with annual sales of $865 million, based on IQVIA MAT September 2024 data. • The drug will be manufactured in Lupin’s Somerset facility in the United States, ensuring a domestic supply of this critical medication.